Zydus
dedicated to life

Cadila
Healthcare Limited

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

August 16, 2017

BSE Limited
1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: **Press Release**

Dear Sir / Madam,

We enclose herewith a copy of press release dated August 16, 2017 titled "Zydus receives final approval from the USFDA for Tiadylt ER Capsules and Azelastine Hydrochloride Nasal Spray".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**

CADILA HEALTHCARE LIMITED AHMEDABAD

UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above

Zydus
dedicated to life

Press Release

Press Release

Press Release

Zydus receives final approval from the USFDA for Tiadylt ER Capsules and Azelastine Hydrochloride Nasal Spray

Ahmedabad, 16 August 2017

Zydus Cadila has received the final approval from the USFDA to market Tiadylt ER (Diltiazem Hydrochloride Extended-Release, USP) Capsules, in strengths of 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, and 420 mg. Tiadylt ER capsules are used to treat hypertension (high blood pressure), angina (chest pain), and certain heart rhythm disorders. The drug will be manufactured at the group's formulations manufacturing facility at the Pharma SEZ, Ahmedabad.

The group also received the final approval from the USFDA to market Azelastine Hydrochloride Nasal Spray, 137 mcg. Azelastine Hydrochloride is used to relieve nasal symptoms such as runny/itching/stuffy nose, sneezing, and post-nasal drip caused by allergies or other conditions. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

***

For further information please contact :
The Corporate Communications Department

Cadila Healthcare Limited
'Zydus Tower', Satellite Cross Roads, Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines) Fax : +91-79-2686 2365 www.zyduscadila.com

CIN-L24230GJ1995PLC025878